JP2023549394A - 注意欠陥／多動性障害の新規な治療 - Google Patents

注意欠陥／多動性障害の新規な治療 Download PDF

Info

Publication number
JP2023549394A
JP2023549394A JP2023528637A JP2023528637A JP2023549394A JP 2023549394 A JP2023549394 A JP 2023549394A JP 2023528637 A JP2023528637 A JP 2023528637A JP 2023528637 A JP2023528637 A JP 2023528637A JP 2023549394 A JP2023549394 A JP 2023549394A
Authority
JP
Japan
Prior art keywords
adhd
compound
administered
treatment
sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528637A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549394A5 (https=
Inventor
エーギル カールソン，カール
ソルスタインソン，ハラルドゥル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3Z ehf
Original Assignee
3Z ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2017858.8A external-priority patent/GB202017858D0/en
Priority claimed from GBGB2103400.4A external-priority patent/GB202103400D0/en
Application filed by 3Z ehf filed Critical 3Z ehf
Publication of JP2023549394A publication Critical patent/JP2023549394A/ja
Publication of JP2023549394A5 publication Critical patent/JP2023549394A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023528637A 2020-11-12 2021-11-12 注意欠陥／多動性障害の新規な治療 Pending JP2023549394A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2017858.8 2020-11-12
GBGB2017858.8A GB202017858D0 (en) 2020-11-12 2020-11-12 Novel treatments
GBGB2103400.4A GB202103400D0 (en) 2021-03-11 2021-03-11 Novel treatments
GB2103400.4 2021-03-11
PCT/EP2021/081567 WO2022101435A1 (en) 2020-11-12 2021-11-12 Novel treatments of attention deficit/hyperactivity disorder

Publications (2)

Publication Number Publication Date
JP2023549394A true JP2023549394A (ja) 2023-11-24
JP2023549394A5 JP2023549394A5 (https=) 2024-11-19

Family

ID=78649316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528637A Pending JP2023549394A (ja) 2020-11-12 2021-11-12 注意欠陥／多動性障害の新規な治療

Country Status (4)

Country Link
US (1) US20240002369A1 (https=)
EP (1) EP4243826A1 (https=)
JP (1) JP2023549394A (https=)
WO (1) WO2022101435A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023084054A1 (en) * 2021-11-12 2023-05-19 3Z Ehf Treatment of adhd using selective binders of the 11-imidazoline receptor

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236857A (en) * 1961-10-09 1966-02-22 Boehringer Sohn Ingelheim 2-(phenyl-amino)-1, 3-diazacyclopentene-(2) substitution products
JPS5592383A (en) * 1978-11-15 1980-07-12 Beiersdorf Ag Novel substituted 55*22imidazolinee22yl** aminopyrimidine*its manufacture and its use as drug
JPS55154971A (en) * 1979-05-18 1980-12-02 Ciba Geigy Ag Pyrimidine compound* its manufacture* pharmaceutic medicine containing same and its therapeutic use
JPH10218773A (ja) * 1997-02-11 1998-08-18 Eli Lilly & Co 糖代謝低下阻止用医薬製剤
WO2004009090A1 (en) * 2002-07-18 2004-01-29 Vanderbilt University Therapeutic and screening methods employing partial agonism of the ∝-2a adrenergic receptor subtype
JP2004513940A (ja) * 2000-11-14 2004-05-13 エフ．ホフマン−ラ　ロシュ　アーゲー Ｉｐアンタゴニストとしての置換２−フェニルアミノイミダゾリンフェニルケトン誘導体
JP2009524619A (ja) * 2006-01-27 2009-07-02 エフ．ホフマン−ラ ロシュ アーゲー Ｃｎｓ障害の処置のための２−イミダゾールの使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323570A (en) 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236857A (en) * 1961-10-09 1966-02-22 Boehringer Sohn Ingelheim 2-(phenyl-amino)-1, 3-diazacyclopentene-(2) substitution products
JPS5592383A (en) * 1978-11-15 1980-07-12 Beiersdorf Ag Novel substituted 55*22imidazolinee22yl** aminopyrimidine*its manufacture and its use as drug
JPS55154971A (en) * 1979-05-18 1980-12-02 Ciba Geigy Ag Pyrimidine compound* its manufacture* pharmaceutic medicine containing same and its therapeutic use
JPH10218773A (ja) * 1997-02-11 1998-08-18 Eli Lilly & Co 糖代謝低下阻止用医薬製剤
JP2004513940A (ja) * 2000-11-14 2004-05-13 エフ．ホフマン−ラ　ロシュ　アーゲー Ｉｐアンタゴニストとしての置換２−フェニルアミノイミダゾリンフェニルケトン誘導体
WO2004009090A1 (en) * 2002-07-18 2004-01-29 Vanderbilt University Therapeutic and screening methods employing partial agonism of the ∝-2a adrenergic receptor subtype
JP2009524619A (ja) * 2006-01-27 2009-07-02 エフ．ホフマン−ラ ロシュ アーゲー Ｃｎｓ障害の処置のための２−イミダゾールの使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAS REGISTRY NO. 1369509-97-6等, DATABASE REGISTRY [ONLINE], JPN7025004078, 2020, ISSN: 0005685629 *
FARSANG, C., MOXONIDINE: CLINICAL PROFILE, JOURNAL OF CLINICAL AND BASIC CARDIOLOGY, vol. 4, no. 3, JPN6025037907, 2001, pages 197 - 200, ISSN: 0005685628 *
HIRASHIMA, A. ET AL., BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 10, JPN6011068281, 2002, pages 117 - 123, ISSN: 0005685630 *
TAN, C. M. ET AL.: "Heterozygous α2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 99, no. 19, JPN5024005702, 2002, pages 12471 - 12476, ISSN: 0005685627 *

Also Published As

Publication number Publication date
EP4243826A1 (en) 2023-09-20
WO2022101435A1 (en) 2022-05-19
US20240002369A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
US20240252491A1 (en) Novel methods
JP5921539B2 (ja) 下肢静止不能症候群を治療する方法
AU2011313814B2 (en) Combination therapy for the treatment of depression and other non-infectious diseases
EP2754440B1 (en) Medicinal agent for treating amyotrophic lateral sclerosis or preventing progression of phase of amyotrophic lateral sclerosis
KR20190013820A (ko) 일주기 리듬 수면 장애를 치료하는 방법
JP2015007096A (ja) 運動障害の予防および／または治療剤
JP2023549394A (ja) 注意欠陥／多動性障害の新規な治療
TW200938194A (en) Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
US20240130995A1 (en) Novel treatments
CN103002893B (zh) 神经障碍性疼痛的治疗药或预防药
JP5341037B2 (ja) 双極性障害を処置するための医薬を得るためのアゴメラチンの使用
CN116981460A (zh) 注意力缺陷/多动障碍的新颖治疗
CN107735094A (zh) 胱氨酸‑谷氨酸转运蛋白的抑制剂的新用途
CN1893942A (zh) 加波沙朵治疗失眠症的用途
US12042493B2 (en) Pharmaceutical compounds for use in treating Huntington's disease
WO2025093748A1 (en) Use of a calcium channel blocker in the treatment of adhd
HK40101538A (en) Compounds for use in the treatment of attention deficit hyperactivity disorder
HK40101538B (en) Compounds for use in the treatment of attention deficit hyperactivity disorder
WO2023084054A1 (en) Treatment of adhd using selective binders of the 11-imidazoline receptor
CN117120046A (zh) 用于治疗注意力缺陷多动障碍的化合物
CN1980652A (zh) 睡眠障碍的预防和/或治疗剂
JPS5824520A (ja) 精神病治療薬
CN117942336A (zh) Go6976在用于制备抗抑郁药物中的应用
Kamath Study of Anticonvulsant Effect of Simvastatin in Maximal Electroshock and Pentylenetetrazole Induced Seizure Model in Albino Mice
JPWO2018159716A1 (ja) アルコール使用障害の治療薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250910

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250918

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260304